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This paper presents application of optical coherence tomography (OCT) for diagnosis and
monitoring of multiple sclerosis (MS). The peripapillary retinal nerve ﬁbre layer thinning
and the reduced total macular volume analysis are shown. With the course of the MS, the
severity of these abnormalities increases which reﬂects the progressive degeneration of
retinal ganglion cells and nerve ﬁbres. The OCT parameters are sensitive, non-invasive
indicators useful in assessing the progression of inﬂammation and neurodegeneration
in MS.
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Multiple sclerosis (MS) is an inﬂammatory and neurode-
generative disorder of the central nervous system (CNS). The
disease involves the presence of demyelinating lesions and
axonal loss associated with the demise of oligodendrocytes
and astrogliotic proliferation, as well as neurodegeneration.
As a result, multifocal CNS damage occurs disseminated
in space and time, leading to severe neurological deﬁcits
and disability. Although both inﬂammation and nerode-
generation play a role in MS, the dynamics of the two
processes differs. In the early stages of the disease the
inﬂammatory processes predominate. With disease progres-
sion, they slow down whereas the axonal degeneration,* Corresponding author at: Department of Ophthalmology, Nicolaus Co
Poland.
E-mail address: sikorski@doctors.org.uk (B.L. Sikorski).
https://doi.org/10.1016/j.pjnns.2017.10.009
0028-3843/© 2017 Polish Neurological Society. Published by Elsevier Swhich is the main cause of MS-related disability, acceler-
ates [1–3]. Neurological symptoms of MS are not pathogno-
monic for the ﬁnal diagnosis. The main diagnostics criteria
include the conﬁrmed multifocal lesions and the onset of
individual symptoms at different points in time and space
[4]. The presentation of cerebrospinal ﬂuid oligoclonal
bands, abnormal evoked potential and multifocal lesions in
magnetic resonance imaging (MRI) enabled faster diagnosis
[4,5].
The interdependence between focal inﬂammation, diffuse
inﬂammation, and neurodegeneration as well as their relative
contribution to clinical deﬁcits remains ambiguous [6]. As the
damage of oligodendrocytes would lead to the pathology of
MS, its elimination is favourable for preventing axonal
degeneration [7,8].pernicus University, M. Skłodowskiej-Curie 9 St., 85-094 Bydgoszcz,
p. z o.o. All rights reserved.
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used in MS as a potential marker of axonal retinal degenera-
tion. Retinal nerve ﬁbre layer (RNFL) thickness and total
macular volume (TMV) are the most frequently investigated
OCT parameters.
2. Retina and the optic nerve
The retina is a unique structure in a human visual system. It
is developmentally related to the cerebrum, as it differenti-
ates from the two layers of the optic cup, which is the
prominence of the neural tube. Hence, considering the retina
is a part of the CNS, it can be divided into two integral parts:
the ﬁrst, neuroepidermal one, which includes rods and cones
forming the ﬁrst neuron; and the second, cerebral one, which
includes bipolar and ganglion cells forming the second and
third neuron of the optic tract. The axial extensions of
ganglion cells form the nerve ﬁbre layer, stretching to the
optic disc, where they leave the eye as an optic nerve
consisting of 1.0–1.2 million of non-myelinated axons of
retinal ganglion cells. It enters the orbit through the scleral
lamina cribrosa, where the myelin sheaths of the nerve ﬁbres
originate. Histologically, the optic nerve, which contains
axons of ganglion cells, astrocytes, oligodendrocytes and
microglia, shows higher resemblance of the white matter of
the brain rather than of the peripheral nerve [9]. The RNFL
contains only the axons of ganglion cells and glia, without the
myelin sheath, which contributes to its uniqueness. Hence,
the RNFL thickness measurement detects the actual axonal
injury and the results remain unaffected by the presence and
thickness of the myelin sheath. That is way the RNFL may be
the location of choice for the monitoring and assessment of
neurodegeneration.
Axonal and neuronal damage are widely accepted as key
events in the disease course of MS. In clinical practice,
patients presenting with ﬁrst clinical event that is highly
indicative of MS are often diagnosed with clinically isolated
syndrome (CIS). Oberwahrenbrock et al. shows that retinal
neurodegeneration is already detectable in CIS patients
and is dependent but importantly also independent of
clinical relapses i.e. optic neuritis (ON). The present study
is the ﬁrst to investigate intraretinal layer changes or detect
retinal neurodegeneration independent from ON in a larger
cohort of CIS patients. Azevedo et al. indicates that the
thalamus may be a location of early neurodegeneration in
MS. Their data identiﬁed the presence of thalamic atrophy
in radiologically isolated syndrome (RIS), which is highly
indicative of early CNS demyelinating disease and should
be investigated as a metric associated with neurodegener-
ation [10].
The post-mortem analyses report retinal pathology in MS
beyond damage to the RNFL and the ganglion cell layer (GCL).
They indicate that retinal pathology might not only develop as
a consequence of inﬂammatory attack to the anterior optic
pathway causing retrograde axonal and neuronal degenera-
tion with RNFL thinning and retinal GCL, but retina itself may
be a primary target of degenerative or inﬂammatory processes.
Thus, OCT is increasingly being utilised as a marker of axonal
loss in MS treatments trials [11].3. Optical coherence tomography: biophysical
basis of diagnostic imaging
The OCT is the method, which enables the imaging of axonal
loss and injury to the retinal ganglion cells. It is a modern
technique for tissue cross-sectional imaging ﬁrst described in
1991 by Huang et al. from the Fujimoto Laboratory at the
Massachusetts Institute of Technology, USA [12]. The subse-
quent development was rapid and spectacular – the ﬁrst
in vivo human cross-sectional retinal measurements were
taken in 1993 at the University of Vienna, and in 1996, the Carl
Zeiss Meditec company presented the ﬁrst commercially
available time-domain OCT (TdOCT). Then, the Institute of
Physics at the Nicolaus Copernicus University, Poland entered
the stage. Here, the ﬁrst spectral domain optical coherence
tomography (SOCT) for the in vivo retinal imaging was
developed in 1999. In 2002, the ﬁrst in vivo tomograms of
the human eye were obtained by the same researchers [13,14].
OCT is basically similar to the ultrasonography examination.
The difference, however, lies in using the light waves (instead
of the sound wave) for tissue penetration. Like in ultrasound,
the wave return time is measured, after it has been reﬂected
and scattered throughout the imaged tissue. As the scanning
beam velocity is very high (the light wave velocity is approx.
300,000 km/s, as compared to the velocity of the sound in
water of 1500 m/s), a direct measurement of the wave return
time is virtually impossible. Instead, wave interference is
utilised for these measurements. OCT can be classiﬁed
according to the measurement method into the originally
developed TdOCT, and a newer SOCT. In TdOCT, the reference
mirror is movable. By changing its distance from the
photodetector it is possible to compare the light beam reﬂected
by the mirror to the light beam returning from the eye. It
enables a precise assessment of distances and a thickness of
individual tissue structures. In SOCT, a movable reference
mirror is absent and the diffractive grid is introduced and a
light beam measurement is taken differently, utilising the
Fourier transform [15]. As a result, the SOCT images yield
much higher resolution, and the acquisition time of a single
1024-point line (a single A-scan) is only 19 microseconds, being
250-fold shorter as compared to TdOCT.
4. TdOCT ver. SOCT in retinal evaluation
TdOCT is a method, which enables acquisition of lower
resolution retinal tomograms, as compared to the SOCT, with
the relatively longer procedure duration. The axial resolution
of TdOCT devices used in ophthalmology is approx. 10 mm
with the transverse resolution of 20 mm (Fig. 1), whereas the
axial resolution of SOCT Copernicus HR (Optopol, Poland) is
3 mm with the transverse resolution ranging from 12 to 18 mm
(Fig. 2.). The number of A-scans per second obtained using
TdOCT is usually up to 500, whereas Copernicus HR acquires
52,000 A-scans per second [16]. Owing to the high resolution of
SOCT, as well as a short examination time, which implies
elimination of the eye movement-related artefacts, it is
possible to obtain the high quality scans which enable the
precise morphological assessment of the analysed tissue and
Fig. 2 – SOCT Copernicus HR: a cross-sectional image of the macula.
Fig. 1 – TdOCT Startus: a cross-sectional image of the macula.
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contactless, reproducible and non-invasive, which contributes
to its common use. Due to high resolution and precision, OCT
is often referred to as ‘‘optical biopsy’’, as the retinal structure
presented in the scans shows high correlation to its actual
histology.
The ﬁrst measurements of RNFL thickness using the TdOCT
were taken as a single peripapillary scan along a ring with a
diameter of 3.4 mm. Due to low precision of measurements
and the low reproducibility of the results, triple circular scans
of the same size were introduced in 2002. The ﬁnal outcome of
the examination was the mean of the three measurements.
Since the SOCT launch, the entire optic disc and the
peripapillary area is scanned and after the automated
centration, the acquired images are precisely analysed. This
imaging and result processing technique signiﬁcantly in-
creased the reliability and reproducibility of the test, which
contributed to the common use of SOCT in all conditions
involving nerve ﬁbre loss. Due to the possibility of optic disc
analysis and a precise RNFL measurement, SOCT is particu-
larly useful in diagnosis and monitoring of optic nerve
diseases. It is utilised in glaucoma, MS and other diseases
causing optic nerve damage, including: ischaemia, post-
traumatic injuries, brain tumours, Alzheimer and Parkinson
disease. The innovative spectral domain imaging is superior to
the conventional technique with respect to data acquisition
speed, resolution and reproducibility. Bock et al. compared ofthe two techniques in 55 MS patients. The result from the two
devices is not interchangeable [17].
5. TdOCT and SOCT in RNFL evaluation in MS
The ﬁrst report on evaluating the RNFL in patients with MS
using the TdOCT was published in 1999. Parisi et al. [18]
examined 14 patients diagnosed with MS, with the history of
previous retrobulbar ON and 14 healthy subjects. The RNFL
was assessed in MS patients both in eyes with the history of
previous retrobulbar ON and in eyes without previous ON
episodes. The mean RNFL thinning in eyes with the history of
ON as compared to the control group and as compared to the
patients with MS without the history of ON was 46% and 28%,
respectively. At the same time, the RNFL thickness in these
patients was lower by 26%, as compared to the same
measurements in healthy controls. Trip et al. found in their
studies that the RNFL thinning in eyes with the history of ON
can be attributed to the axonal loss in an optic nerve [19,20].
Other authors conﬁrmed the peripapillary RNFL thinning in
eyes with the history of ON as compared to both healthy
individuals and MS patients without the history of ON [21–24].
Different publications report also the RNFL thinning in
patients with MS who did not have previous retrobulbar ON
[21,25]. Our results also show that during the natural course of
MS statistically signiﬁcant RNFL reduction occurs both in eyes
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presents the SOCT report showing the mean peripapillary
RNFL thickness (TSNIT), the RNFL thickness in individual
sectors (expressed both as numbers and on the graph with the
indicated normative values), and the optic disc parameters.
The noticeable abnormalities include the decreased TSNIT
graph and the RNFL thinning in particular sectors of the right
eye with the history of ON and the decreased TSNIT in the left
eye. The mean RNFL thinning in case with and without the
history of ON was 23.3% and 9.5%, respectively [26].
In one of their ﬁrst reports, Reich et al. observed a
correlation between the optic radiation damage shown in
MRI and RNFL atrophy in the respective eye [27]. The authors
claim that it is the evidence of a secondary, trans-synaptic
damage to the ganglion cell axons and the peripapillary RNFL
thinning due to the degenerative process, which involves the
optic tract even in eyes without clinical episodes of ON. InFig. 3 – SOCT Copernicus HR: analysis of peripapillary RNFL thick
the right eye.another study, Gordon-Lipkin et al. examined 40 patients
diagnosed with MS and found an association between the MRI-
conﬁrmed cerebral atrophy and the peripapillary RNFL
atrophy [28]. The authors suggested, that the RNFL thickness
assessment using OCT enables obtaining reliable information
regarding the neurodegenerative brain lesions, which develop
in MS. These results correspond with the ﬁndings of other
investigators, who conﬁrmed that the peripapillary RNFL
atrophy occurs both in eyes after previous ON and in eyes of
patients with MS with no history of ON and that it correlates
with the MRI-conﬁrmed brain atrophy [20,24,25,29–33]. How-
ever, in MS, data on the relation of OCT measures and grey and
white matter volumes are contradictory. Young et al. suggests
that in early MS, OCT measures of retinal atrophy are related to
volumetric changes in the white but not grey matter
compartment as assessed by MRI [34]. Dorr et al. in large
prospective study on 104 relapsing-remitting MS (RRMS)ness in a patient with previous retrobulbar optic neuritis in
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TMV with brain parenchymal fraction (BPF) [35]. RNFL
thickness (RNFL-T) was furthermore linked to disease duration
but neither to disease severity nor patients age. Contrarily BPF
was rather associated with severity than disease duration and
was confounded by age. TMV was not associated with any of
these parameters. RNFL-T might be better parameter for
monitoring axonal damage longitudinally. Gabilondo et al.
evaluated the association between the damage to the anterior
and posterior visual pathway as evidence of the presence of
trans-synaptic degeneration in MS [36]. The voxel-based
morphometry (VBM) showed that RNFL-T was speciﬁcally
associated with atrophy of the visual cortex and with lesions in
optic radiation of study inclusion. Patients with severe prior
ON had a lower adjusted mean visual cortex volume than
patients without ON. Zimmermann et al. investigated the
association of white and grey matter brain volume with
peripapillary RNFL and GCL in 63 patients with RRMS [37]. Both
parameters – RNFL and GCL in eyes without previous ON are
comparably linked to whole brain as well as white and grey
matter atrophy. An event of ON interferes with this relation.
Sinnecker el al studied 75 MRI, OCT, optic radiation volume,
optic radiation thickness and visually evoked potentials in 30
patients (26 RRMS and 4 CIS). The authors conﬁrmed that both
anterior visual pathway damage and optic radiation integrity
loss detectable by MRI are common ﬁndings in MS patients
[38]. Saidha et al. investigated dynamic changes including OCTFig. 4 – Comparison of peripapillary RNFL thickness measured by
in right eye. There is no progression of RNFL atrophy at 18 mon(including automated macular segmentation), MRI (including
brain structure volumetrics) in 107 MS patients biannually
(median follow-up 46 months) [39]. The ganglion cell plus
inner plexiform layer (GCIP) and whole-brain (as well as grey
and white matter) atrophy rates were more strongly associated
in progressive MS than RRMS. They support the utility of OCT
for clinical monitoring in investigative trials. Scheel et al.
investigated the association of RNFL thickness with white
matter damage assessed by diffusion tensor imaging in MS.
They demonstrated that RNFL changes indicate white matter
damage exceeding the visual pathway [40]. Owing to precision
and reproducibility of the peripapillary RNFL thickness mea-
surement, SOCT offers a reliable evaluation of RNFL atrophy
progression (Fig. 4). As a result, it is possible to assess both the
pace of neurodegeneration and the response to treatment.
It should be emphasised that the RNFL thinning is not
pathognomonic for the optic nerve atrophy secondary to MS.
As conﬁrmed by Choi et al. [41], all types of optic neuropathy –
either ischaemic, toxic, post-traumatic or inﬂammatory
unrelated to MS – are associated with the peripapillary RNFL
thinning.
6. SOCT for macular evaluation
Another point of interest for the neuroophthalmologists
studying MS is the retinal area located temporally to the optic SOCT in a patient with a history of retrobulbar optic neuritis
ths interval.
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the retina (diameter about 2.85 mm) and has the natural pit in
the middle, which is referred to as the fovea (Fig. 5). The
perifoveal area of 0.5 mm is the only part of the retina where
the GCL is composed of 5–7 cell layers rather than a single cell
layer, which is the case in other portions of the retina [42]. That
is why it makes this region an ideal target site for assessing
neurodegeneration processes.
The TMV is one of the parameters evaluated by SOCT
in the perimacular area. Fig. 6 shows the TMV, as well as
retinal thickness and volume in individual measurement
sectors (expressed both as numbers and on the graph). The
noticeable abnormalities involve a signiﬁcant TMV decrease
and retinal thinning in the peripheral measurement rings
of the right eye with the history of previous ON. The ﬁrst
reports on TMV were published in 2005. Trip et al. examined 25
patients with the history of ON followed by an incomplete
visual recovery. They found that the TMV was statistically
signiﬁcantly lower in eyes with the history of ON, as compared
to the eyes without previous ON or controls [20]. Our results
also indicate that MS causes TMV reduction, which is the
largest in eyes with the history of previous ON. However, this
decrease is also present and remains statistically signiﬁcant
even in eyes without previous ON [26]. These results
correspond with the ﬁndings of other investigators, who
conﬁrmed that the TMV reduction occurs both in eyes after
previous ON and in eyes of patients with MS but without a
history of ON [25,27,30,32,43]. The highly heterogeneous
disease course in MS may be explained by diverse pathologi-
cal processes, such as the amounts of de- and remyelination
but also the degree of axonal and neuronal damage. Some
previous studies have compared the RNFL thickness and TMV
between the different MS disease types. More recent studies
reported the most severe atrophy of the RNFL and GCIP in
secondary progressive MS (SPMS) rather than in primary
progressive MS (PPMS) [44–46]. Saidha et al. identiﬁed a
unique subset of patients with MS in whom there appears to
be disproportionate thinning of the inner and outer nuclearFig. 5 – Fundus colour photograph showing the optic disc
and the macula (encircled area) with the centrally located
fovea.layers which may be occurring as a primary process
independent of optic nerve pathology [47]. Patients with
greater inner and outer pathology appear to have a predilec-
tion towards a more accelerated rate of disability progression.
Brandt et al. analysed their datasets from a large cohort of 370
patients with MS (262 RRMS, 61 SPMS, 36 PPMS and 11 CIS) and
71 healthy controls, investigated with a latest generation
SOCT system (Specralis OCT, Heidelberg Engineering,
Germany) at three large academic MS centres in Germany
[48]. They examined whether the proposed macular thinning
predominant phenotype and its frequency were also observed
in their cohort. Interestingly only 6/17 (35.3%) of patients with
PPMS fulﬁlled the macular thinning predominant criteria, in
contrast to Saidha et al., who did not ﬁnd the macular
thinning predominant phenotype among their PPMS cohort.
This results do not support the conclusion of a distinct
macular thinning predominant OCT phenotype in MS.
Patients displaying the macular thinning predominant
phenotype when measured with Cirrus OCT (Carl Zeiss
Meditec, Germany), could be re-evaluated with Spectralis
OCT to determine whether differences in instruments and
scanning methodologies might be of importance. Balk et al.
conﬁrmed that thinning of the inner retinal layers (RNFL, GCC
and inner nuclear layer) is signiﬁcantly inﬂuenced by the
heterogeneous disease course in MS [49]. Oberwahrenbrock
et al. pointed out the effect size of the association of disease
duration and RNFL thickness or TMV in MS-NON (no optic
neuritis) eyes only. They showed the strongest and highly
signiﬁcant changes for RNFL thickness and TMV (for SPMS not
signiﬁcant correlation in TMV change). However, correlation
of RNFL and TMV with disease duration were not signiﬁcant
for PPMS-NON eyes [46]. Considering the speciﬁc histology of
the retina in the perimacular area, an assumption that the
changes in retinal thickness and TMV reﬂect not only the
retinal nerve ﬁbre loss but also ganglion cell loss, appears
reasonable. Some authors claim that the TMV reduction
shows that the primary damage in MS involves the retinal
ganglion cells and is later followed by the nerve ﬁbre damage
(axons). Owing to further development of SOCT, the research
is being conducted into potential segmentation of retinal
layers in the perifoveal area and the possibility to assess the
macular ganglion cell complex (GCC) composed of ganglion
cells and the inner plexiform layer (GCIP) (Fig. 7). Walter et al.
[50] observed a statistically signiﬁcant GCC thinning in MS
patients as compared to the controls, which correlated with
their visual acuity and the subjectively assessed quality of life.
Syc et al. [51] showed that the GCC atrophy commonly found
in patients with MS and NMO (neuromyelitis optica) was also
present in individuals without the history of ON. This appears
to conﬁrm the hypothesis that the degenerative process in
these diseases causes both axonal and neuronal injury within
the retina, regardless of previous ON, which may only lead to
the deterioration of pre-existing pathology. Another essential
ﬁnding from this study was the absence of oedema during the
retrobulbar ON within the ganglion cell and inner plexiform
layers. The oedema usually develops within the RNFL in acute
stage of ON and signiﬁcantly limits the neurodegeneration
assessment based on the peripapillary RNFL thickness
measurement. However, the assessment of the GCC thickness
is not subject to this limitation. Hence, it is superior to RNFL
Fig. 6 – Total macular volume (TMV) obtained by SOCT Copernicus HR in a patient with a history of ON of the right eye 2 years
earlier.
Fig. 7 – SOCT Copernicus HR: cross-sectional image of the macula with the marked ganglion cell layer and the inner plexiform
layer which form the ganglion cell complex (GCC).
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tion. Schneider et al. investigated retinal changes in eyes of
NMO spectrum disorders patients and compared them to
matched RRMS patients and healthy controls [52]. RNFL
thickness was more severely reduced in NMO compared to MS
following ON. In MS-ON eyes, RNFL thinning showed a clear
temporal preponderance, whereas in NMO-ON eyes RNFL
was more evenly reduced. The inner nuclear layer and the
outer retinal layers were thicker in NMO-ON patients
compared to NMO without ON, while these differences were
primarily driven by microcystic macular oedema (MMO).
However, OCT is still insufﬁcient to help with the clinically
relevant differentiation of both conditions in an individual
patient. Numerous studies showed that ON in NMO typically
results in more severe RNFL and GCL thinning and more
frequent development of MMO than in MS [53]. RNFL thinning
also occurs in the absence of ON in MS, subclinical damage
seems to be rare in NMO. OCT might be useful in differentiat-
ing NMO from MS. Ratchford et al. showed a signiﬁcant GCC
thinning in patients with early, active MS. They suggest
that the MS-related retinal lesions reﬂect the severity of
neurodegeneration within the CNS [44]. The current studies
also show that thinning of the RNFL and other retinal layers
shown in SOCT correlate with the brain volume changes
secondary to MS, observed in brain MRI [54]. Therefore, they
can be a sensitive marker of progression for the assessment
of neurodegeneration in patients with MS. However, the SOCT
showed not only retinal layers atrophy but also other
abnormalities in patients with SM. Gelfand et al. [55] observed
MMO in about 5% of patients with MS (unrelated to MS-
induced uveitis). Tiny pseudocystic lesions were located
within the inner nuclear layer that is composed of bipolar,
amacrine, horizontal and Muller cells, mainly in patients
with the history of ON. The presence of MMO may be
indicative of the inﬂammatory and degenerative type of
demyelination in patients with MS. They were associated
with greater disease severity and decreased visual acuity.
According to Saidha et al. the increased thickness of the inner
nuclear layer and the presence of MMO observed in SOCT
correlate with the activity and relapses of MS, the onset of
enhancing Gd+ focal lesions in MRI as well as disability
progression [56]. The recent discovery that antibodies to
myelin oligodendrocyte glycoprotein (MOG) are detected in
some NMO IgG-seronegative patients manifesting clinical
and neuroimaging signs of NMO or NMO spectrum disorders
(NMOSD) represents a variant of opticospinal MS or acute
disseminated encephalomyelitis. This poses the question
whether the MOG-IgG positive, AQP4-seronegative pheno-
type patients should be classiﬁed as NMOSD? [57] Rama-
nathan et al. conﬁrmed the presence of MOG antibodies in 9/
23 AQP4 antibody negative patients with NMO/NMOSD,
compared to 1/17 patients with MS and 0/52 controls. MOG-
antibody-positive patients had prominent optic disc swelling
and were more likely to have a rapid response to steroid
therapy and relapse on steroid cessation than MOG antibody-
negative patients. MOG antibodies have a strong association
with bilateral and/or recurrent ON [58]. Chalmoukou et al.
conﬁrmed that anti-MOG antibodies are frequently associat-
ed with recurrent forms of ON or chronic relapsing inﬂam-
matory ON [59].7. Conclusions
The SOCT studies show, that regardless of previous retro-
bulbar ON, each case of MS involves the peripapillary RNFL
thinning, accompanied by the reduced TMV. With the course
of the disease, the severity of these abnormalities increases,
which reﬂects the progressive degeneration of retinal ganglion
cells and nerve ﬁbres. The changes of the abovementioned
parameters can be a sensitive, non-invasive indicator useful in
assessing the progression of inﬂammation and degeneration
in MS, being the additional marker for treatment monitoring,
which is currently used in patients with relapsing-remitting
MS treated with disease modifying drugs.
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